What do you Know about Weight Loss Medications?

Article

Weight loss is essential to arrest the cardiovascular disease and metabolic dysfunction linked to obesity. What do you know about the drugs now available that may help?

With overweight and obesity reaching epidemic levels in the United States and the strong association between excess adiposity and cardiovascular disease, weight loss is recommended by professional societies as part of a heart health plan for at-risk patients. Weight-loss drugs are a valuable part of that plan when used appropriately. How much do you know about dosage, interactions, and safety warnings? Take this quiz and find out!

Recent Videos
New Research Amplifies Impact of Social Determinants of Health on Cardiometabolic Measures Over Time
Overweight and Obesity: One Expert's 3 Wishes for the Future of Patient Care
Donna H Ryan, MD Obesity Expert Highlights 2021 Research Success and Looks to 2022 and Beyond
"Obesity is a Medically Approachable Problem" and Other Lessons with Lee Kaplan, MD, PhD
Related Content
GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

GLP-1 Therapy for Obesity Requires Substantial Nutritional Framework, Multidisciplinary Support, Joint Advisory Warns

Grace Halsey
July 9th 2025
Article

GLP-1 medications are transforming obesity medicine but strong evidence points to a need for integrating nutrition and lifestyle support for lasting weight loss and health benefits.

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Navigating Cardiovascular Complications of Obesity: Expert Insights for Primary Care

Sydney Jennings
August 30th 2023
Podcast

Listen to our latest podcast episode for details on top CVD risk factors to screen patients with obesity for, medications to help prevent CVD, and more.

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Novel GLP-1/GLP-2 Agent Reduces Body Weight by Up to 8.3% in Phase 1b Obesity Trial

Sydney Jennings
July 7th 2025
Article

ADA 2025: Dapiglutide showed promising safety and weight loss results in a phase 1b trial, targeting obesity and inflammation with once-weekly dosing.

Obesity & Type 2 Diabetes: An Expert Discussion

Obesity & Type 2 Diabetes: An Expert Discussion

Sydney Jennings
June 30th 2023
Podcast

In our latest episode, 2 obesity experts discuss the importance of early intervention to reduce risk for complications, suggestions for managing patients in primary care, and more.

Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity / image credit ©Viking Therapeutics

Viking Advances GLP-1/GIP Agonist VK2735 into Late Stage Clinical Program for Obesity

Grace Halsey
June 26th 2025
Article

Viking Therapeutics initiates phase 3 trials for VK2735, a promising dual incretin agonist targeting obesity and other metabolic disorders, based on strong phase 2 findings.

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Mifepristone Reduced HbA1c, Body Weight in Adults with Hypercortisolism and Inadequately Controlled T2D: CATALYST Trial Treatment Phase

Sydney Jennings
June 24th 2025
Article

ADA 2025: Mifepristone lowered HbA1c levels by about 1.5% over 24 weeks vs placebo among participants with hypercortisolism and inadequately controlled T2D.

© 2025 MJH Life Sciences

All rights reserved.